Several gene mutations associated with PD are worthy of consideration as targets for therapeutic intervention, but interestingly, the latest gene therapies have applied the same target to LRRK2, particularly the LRRK2 G2019S mutation. This evidence concerns the gene LRRK2 and Parkinson disease.